Amgen (AMGN) Tops Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Sandisk unveils underwhelming outlook despite AI demand surge; shares slip
- Alphabet taps bond market with sweeping 10-part offering to fuel AI ambitions
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Apollo to acquire easyJet for £5.7B in cash deal
- Nielsen to acquire DoubleVerify in merger deal
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Stocks close lower as investors eye Mideast talks, earnings
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Amgen Reports First Quarter 2020 Financial Results
April 30, 2020 4:01 PM EDTTHOUSAND OAKS, Calif., April 30, 2020 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the first quarter of 2020 and discussed the company's response to the COVID-19 pandemic.
First Quarter Performance
Key results include:
Total revenues increased 11% to $6.2 billion in comparison to the first quarter of 2019, driven by higher unit demand, offset partially by lower net selling prices. Product sales increased 12% globally, driven by volume growth across a number of our newer products, including Otezla® (apremilast), Repatha® (evolocumab), MVASI® (bevacizumab-awwb), KANJINTI® (trastuzumab-anns)... More